Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-day artesunate-pyronaridine plus sulfadoxine-pyrimethamine for uncomplicated malaria
PACTR202405571736678Phase 3Recruiting
- Sponsor
- Centre de Recherches Médicales de Lambaréné
- Start
- May 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of artesunate, pyronaridine, sulfadoxine, pyrimethamine, artemether and 1 more in malaria (2 arms), sponsored by Centre de Recherches Médicales de Lambaréné. Primary endpoint: Day 28 PCR-adjusted adequate clinical and parasitological response. Started May 2024; status: recruiting.
02
Drugs
artesunatepyronaridinesulfadoxinepyrimethamineartemether
03
Conditions
malaria
Beyond the preview
Go deeper on PACTR202405571736678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202405571736678.